Every 8-K that LeMaitre Vascular, Inc. (LMAT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LMAT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LMAT filings page.
LeMaitre Vascular reported strong preliminary, unaudited Q2 2026 results. Net sales were about $70.4M versus $64.2M a year earlier, with net income of $17.1M and diluted EPS of $0.74 versus $0.60. Gross margin reached 72.1%, up 210 bps, and adjusted EBITDA was $22.8M, up 20%.
Growth was led by Artegraft sales up 34%, record grafts, shunts and patches, and double-digit gains in EMEA and APAC. Organic growth excluding catheters was 12%; catheters declined 11% after prior-year recall overstocking. Cash and short-term marketable securities totaled roughly $376M and stockholders’ equity was $420.3M.
The board declared a $0.25 per-share quarterly dividend payable September 3, 2026 and previously authorized up to $100M of share repurchases through February 2027. Guidance calls for 2026 sales of $274.3M–$278.3M (midpoint $276.3M, about 11% growth) and EPS of $2.84–$2.94 (midpoint $2.89), implying 15% GAAP and 21% adjusted EPS growth versus 2025.
LeMaitre Vascular, Inc. reported the results of its 2026 Annual Meeting of Stockholders. A total of 22,847,798 shares were entitled to vote as of April 6, 2026, and 21,336,301 shares were represented in person or by proxy.
Stockholders elected two Class II directors to three-year terms: David B. Roberts received 18,888,412 votes for and 1,250,012 withheld, while John A. Roush received 14,229,071 votes for and 5,909,353 withheld. An advisory vote approved executive compensation with 19,311,813 votes for and 813,052 against. Stockholders also ratified Grant Thornton LLP as independent registered public accounting firm for 2026 with 21,220,412 votes for and 108,474 against.
LeMaitre Vascular, Inc. reported strong preliminary Q1 2026 results with net sales of $66.6M, up from $59.9M, driven by 11% sales growth and broad strength across products and regions. Artegraft sales grew 36% worldwide, while grafts, valvulotomes, and carotid shunts each set record sales.
Gross margin reached 72.7%, up 350 basis points, and operating income rose to roughly $17.8M, a 41% increase. Diluted EPS grew 42% in Q1. Management’s guidance implies full-year 2026 sales growth of 12% and adjusted EPS growth of 26%, with Q2 sales expected around $71.5M at the midpoint.
The board approved a quarterly dividend of $0.25 per share payable on June 4, 2026, and authorized a share repurchase program of up to $100M through February 18, 2027. The company also highlighted non-GAAP metrics such as adjusted EBITDA and organic sales growth.
LeMaitre Vascular, Inc. reports upcoming changes to its Board of Directors tied to the 2026 Annual Meeting of Stockholders on June 2, 2026. Bridget Ross, a Class II director, has informed the Board she will not stand for re-election and will serve until her current term ends at that meeting. The company states her decision is not due to any disagreement regarding operations, policies, or practices.
To rebalance the staggered board, the Board has nominated David B. Roberts to stand for election as a Class II director at the same meeting. In connection with this nomination, Mr. Roberts has indicated he will resign as a Class I director at the conclusion of the meeting, contingent on his election as a Class II director. After these changes, the Board will have seven members instead of eight, structured as two Class I directors, two Class II directors, and three Class III directors, consistent with the company’s charter and by-law provisions allowing the Board to set its own size.
LeMaitre Vascular reported strong Q4 2025 and full-year 2025 results while boosting shareholder returns and offering upbeat 2026 guidance. Q4 net sales reached $64.5m, up from $55.7m, with grafts, valvulotomes, and carotid shunts driving 16% sales growth and a gross margin of 71.7%.
Q4 operating income rose to $18.8m, up 47%, and full-year net sales increased to $249.6m from $219.9m. Full-year net income grew to $57.7m, with diluted EPS rising to $2.52 from $1.93, reflecting solid operating leverage.
The board raised the quarterly dividend by 25% to $0.25 per share, payable on March 26, 2026, and authorized a share repurchase program of up to $100m through February 18, 2027. For 2026, the company guides to mid-point sales of $280m (about 12% growth) and operating income of $77.8m, with projected diluted EPS of $2.91.
LeMaitre Vascular, Inc. filed an amendment to its prior report to disclose its Board of Directors’ decision on how often shareholders will vote on executive pay. At the 2025 annual meeting, stockholders indicated a preference for holding the non-binding advisory Say-on-Pay vote every year.
After considering this stockholder vote, the Board determined that LeMaitre Vascular will conduct future Say-on-Pay votes on an annual basis. No other changes were made to the original report of the 2025 Annual Meeting voting results.
LeMaitre Vascular furnished a press release detailing its preliminary financial and operational results for the quarter ended September 30, 2025. The disclosure is provided under Item 2.02 and is not deemed “filed” for Section 18 purposes, nor incorporated by reference except as expressly set forth.
The report includes Exhibit 99.1 (press release) and Exhibit 104 (Inline XBRL cover page data) and contains a forward-looking statements disclaimer.